During the past decade, Hôpital Larrey;Université Paul Sabatier conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hôpital Larrey;Université Paul Sabatier" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Adenocarcinoma" (1 trials), "Adenocarcinoma, Papillary" (1 trials), "Bronchial Neoplasms" (1 trials) and "Carcinoma" (1 trials). Many other conditions were trialed in "Hôpital Larrey;Université Paul Sabatier" in a lesser frequency.

Most popular intervention types in "Hôpital Larrey;Université Paul Sabatier" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Apremilast 20mg" (1 trials), "Apremilast 30mg" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Bevacizumab" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Larrey;Université Paul Sabatier" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Hôpital Larrey;Université Paul Sabatier". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hôpital Larrey;Université Paul Sabatier, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Larrey;Université Paul Sabatier, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".